NYMC Faculty Publications

Interleukin 1β: A Proinflammatory Target for Preventing Atherosclerotic Heart Disease

Author Type(s)

Faculty

DOI

10.1097/CRD.0000000000000022

Journal Title

Cardiology in Review

First Page

176

Last Page

181

Document Type

Article

Publication Date

1-1-2014

Department

Medicine

Keywords

Animals, Anti-Inflammatory Agents, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Coronary Artery Disease, Disease Models, Animal, Humans, Interleukin 1 Receptor Antagonist Protein, Interleukin-1beta, Lipid Metabolism, Mice, Randomized Controlled Trials as Topic, Risk Factors

Disciplines

Medicine and Health Sciences

Abstract

Interleukin 1β (IL-1β) is a proinflammatory cytokine that has been implicated in a number of rheumatologic and inflammatory conditions. The production and secretion of IL-1β from inflammatory cells is a tightly regulated process that has been extensively described and studied. In recent years, IL-1β has been associated with several steps in the development of atherosclerotic plaques, as well as other cardiovascular disease modifiers, such as cigarette smoking and type II diabetes mellitus. More recently, IL-1β has become the target of therapy in refractory rheumatologic conditions and is under investigation as a potential target of therapy in cardiovascular disease. The Canakinumab Anti-inflammatory Thrombosis Outcomes Study is currently underway and strives to use canakinumab, a monoclonal antibody directed against IL-1β, to evaluate the inflammatory hypothesis of cardiovascular disease. If the trial meets its primary end points (eg, significant reductions in nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death), the Canakinumab Anti-inflammatory Thrombosis Outcomes Study will confirm the critical role of IL-1β-mediated inflammation in the development of cardiovascular disease and will introduce cytokine-directed therapy as a potential avenue for the treatment of atherosclerotic disease.

Link to Full Text

Share

COinS